Sensitivity and specificity to amphetamine of a french version of the 49-item form of the addiction research center inventory

Warot, D.; Danjou, Philippe; Payan, Christine; Puech, A

doi:10.1016/s0376-8716(97)01358-6

Cited by 6 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the motor score was not significantly different between the on ‐levodopa or on‐stimulation conditions, whereas ARCI scores were improved to a greater extent with levodopa than with stimulation. Moreover, the amphetamine subscore, indicating euphoria and psychic stimulation, was higher in PD patients on‐stimulation compared to a control group from the literature 42. Furthermore, major psychotropic effects related to DBS can occur acutely that cannot be explained by changes in the motor state.…”

Section: Discussionmentioning

confidence: 86%

“…We chose the ARCI because it has the advantage of being largely independent of the motor state and can be used repetitively 29, 42. Contrary to depression scales such as the Beck scale or the depression items of the UPDRS,31 which assess changes in mood over periods of several weeks, the ARCI allows the assessment of psychotropic changes within a few minutes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease

et al. 2003

View full text Add to dashboard Cite

High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves the motor symptoms of Parkinson's disease (PD). Opposite changes in mood, such as mania or depression, have been reported after surgery, but it is not known whether these side effects are specifically related to STN DBS. To learn whether STN DBS also influences the limbic loop, we investigated acute subjective psychotropic effects related to levodopa or bilateral STN DBS. After a median postoperative follow-up of 12 months, 50 PD patients completed the Addiction Research Center Inventory (ARCI), assessing subjective psychotropic effects in four conditions: off-drug/on-stimulation; off-drug/off-stimulation; on-drug/off-stimulation; and on-drug/on-stimulation. Both levodopa and STN DBS improved all the ARCI subscales, indicating subjective feelings of well being, euphoria, increase in motivation, and decrease in fatigue, anxiety, and tension. A suprathreshold dose of levodopa was significantly more effective than STN DBS, using the same electrical parameters as for chronic stimulation, on four of the five ARCI subscales. We concluded that 1) both STN DBS and levodopa have synergistic acute beneficial psychotropic effects in PD, 2) the psychotropic effects of both treatments need to be considered in the long-term management of chronic STN DBS, and 3) the results indicate an involvement of the limbic STN in mood disorders of PD.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Patients filled out the French version38 of the short form of the ARCI39 in order to assess the acute psychic effects of all conditions of treatment. The ARCI is a true/false questionnaire of 49 items designed to differentiate classes of psychoactive drugs.…”

Section: Methodsmentioning

confidence: 99%

Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease

et al. 2006

View full text Add to dashboard Cite

In Parkinson's disease (PD), levodopa and subthalamic nucleus (STN) stimulation lead to major improvement in motor symptoms. Effects of both treatments on cognition and affective status are less well understood. Motor, cognitive, and affective symptoms may relate to the dysfunctioning of parallel corticostriatal loops. The aim of this study was to assess cognition, behavior, and mood, with and without both treatments in the same group of PD patients. A group of 22 nondemented PD patients was included in this study. Patients were tested twice before surgery (off and on levodopa) and twice 3 months after surgery (OFF and ON STN stimulation, off levodopa). Cognitive and affective effects of STN stimulation and levodopa had some common, but also different, effects. STN stimulation improved performance on the planning test, associated with the dorsolateral prefrontal cortex. However, the treatments had opposite effects on tests associated with the orbitofrontal cortex; specifically, levodopa impaired while STN stimulation improved performance on the extinction phase of a reversal/extinction task. Acutely, both treatments improved motivation and decreased fatigue and anxiety. On chronic treatment (3 months after surgery), depression improved, whereas apathy worsened 3 months after surgery. To conclude, there were significant but contrasting effects of levodopa and STN stimulation on cognition and affective functions.

show abstract

“…The ARCI consists of 49 true‐or‐false questions from which were derived five major scores: morphine‐benzedrine group (a measure of euphoria), pentobarbital‐chlorpromazine‐alcohol group (a measure of sedation), LSD (a measure of dysphoria), and the benzedrine group and amphetamine‐sensitive scores, both for stimulant effects. A French version of the scale validated in healthy subjects was used 26 . SRT was performed at −0.5, 1, 3, and 8 hours; LMT at −0.5 and 4 hours; BL‐VAS at −0.5, 1, and 3 hours; and ARCI at 24 hours.…”

Section: Methodsmentioning

confidence: 99%

Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N‐Methyl‐D‐Aspartate Antagonist, after Single Oral Doses in Healthy Subjects

Tarral

Dostert

Guillevic

et al. 2003

The Journal of Clinical Pharma

View full text Add to dashboard Cite

A double-blind, randomized, placebo-controlled study was performed to assess the safety, tolerability, and pharmacokinetics of single oral doses of CHF 3381 in 56 young healthy male volunteers. The central nervous system effects of CHF 3381 were also evaluated, as well as the effect of food on the rate and extent of CHF 3381 absorption. Seven doses of CHF 3381 (25, 50, 100, 200, 300, 450, and 600 mg) were evaluated in an escalating order. At each dose level, 6 subjects were given CHF 3381, and 2 subjects were given placebo. Safety and tolerability evaluation included adverse events, physical examination, vital functions, electrocardiogram, laboratory tests, and 24-hour Holter (100-mg and 450-mg dose panels). Plasma and urinary concentrations of CHF 3381 and its two main metabolites (CHF 3567 and 2-aminoindane) were measured with a validated high-performance liquid chromatography method. Central nervous system effects were evaluated with the simple reaction time (SRT); learning memory task (LMT); Bond & Lader Visual Analog Scale for alertness, contentedness, and calmness; Addiction Research Center Inventory (ARCI); and electroencephalogram. There were no serious adverse events; the most frequent adverse events were dizziness, abnormal thinking, and asthenia. The number of adverse events with moderate intensity increased sharply with the dose, with no or few events up to 450 mg and 17 events with 600 mg. Therefore, 600 mg was defined as the maximum tolerated dose. There were no significant treatment effects on cardiovascular function and electrocardiogram parameters at any CHF 3381 dose or on oral temperature or laboratory tests. There were no clinically significant changes in laboratory variables. CHF 3381 was absorbed rapidly (tmax = 0.5-2 h) and cleared from plasma with a half-life of 3 to 4 hours. Plasma levels of CHF 3381 and its two major metabolites were found to be proportional to the dose. 2-Aminoindane formed slowly and reached much lower concentrations compared to the parent compound and the other metabolite (CHF 3567). Within 48 hours after dosing, 2% to 6% of the administered dose was found in the urine as unchanged drug, about 50% to 55% as the acid derivative (CHF 3567), and 2% to 3% as 2-aminoindane. Ingestion of food did not affect the extent of absorption of the drug, while the rate of absorption was considerably reduced (tmax = 4 h). No significant effects of CHF 3381 were observed on attention (SRT) or memory (LMT). Visual analog scales revealed a decreasing effect of CHF 3381 on alertness at 1 hour that reached statistical significance at 300 and 600 mg. EEG spectral analysis revealed minor decreasing effects of the 200-mg dose on total electric power measured at 2 hours. A stimulant effect was detected by the ARCI scale 24 hours after the 300-mg dose and might be related to the slow formation of the 2-aminoindane metabolite. In conclusion, this study has shown that the maximum tolerated dose of CHF 3381 after single oral administration in young healthy male volunteers is 600 mg. CHF 3381 displ...

show abstract

Sensitivity and specificity to amphetamine of a french version of the 49-item form of the addiction research center inventory

Cited by 6 publications

References 15 publications

Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease

Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease

Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease

Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N‐Methyl‐D‐Aspartate Antagonist, after Single Oral Doses in Healthy Subjects

Contact Info

Product

Resources

About